Efficacy of high-dose methylprednisolone in patients with Crimean-Congo haemorrhagic fever and severe thrombocytopenia

Tropical Doctor

Volumn 43, Issue 2, 2013, Pages 49-53

  Sharifi Mood, Batool ^a   Alavi Naini, Roya ^a   Metanat, Maliheh ^a   Mohammadi, Mehdi ^a   Shakeri, Asad ^a   Amjadi, Ali ^a  

^a ZAHEDAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

CCHF; Crimean Congo haemorrhagic fever; methyl prednisolone; prednisolone; ribavirin; thrombocytopenia

Indexed keywords

IMMUNOGLOBULIN M; METHYLPREDNISOLONE; RIBAVIRIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CRIMEAN CONGO HEMORRHAGIC FEVER; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MEGADOSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LEUKOCYTE COUNT; MALE; MORNING DOSAGE; MORTALITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE DRUG DOSE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT OUTCOME;

CCHF; CRIMEAN-CONGO HAEMORRHAGIC FEVER; METHYL PREDNISOLONE; PREDNISOLONE; RIBAVIRIN; THROMBOCYTOPENIA;

ADMINISTRATION, ORAL; ADULT; AGED; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HEMORRHAGIC FEVER, CRIMEAN; HUMANS; MALE; METHYLPREDNISOLONE; MIDDLE AGED; RIBAVIRIN; THROMBOCYTOPENIA; YOUNG ADULT;

EID: 84880421219     PISSN: 00494755     EISSN: 17581133     Source Type: Journal    
DOI: 10.1177/0049475513486642     Document Type: Article

References (20)

1. Mardani M, Keshtkar-Jahromi M. Crimean-Congo hemorrhagic fever. Arch Iran Med 2007; 10: 204-214.
2. Alavi-Naini R, Moghtaderi A, Koohpayeh HR et al. Crimean-Congo hemorrhagic fever in southeast of Iran. J Infect 2006; 52: 378-382.
3. Sharifi-Mood B, Mardani M, Keshtkar-Jahromi M et al. Clinical and epidemiologic features of Crimean-Congo hemorrhagic fever among children and adolescents from South eastern Iran. Pediatr Infect Dis J 2008; 27: 561-563.
4. Sharifi-Mood B, Metanat M, Ghorbani-Vaghei A et al. The outcome of patients with Crimean-Congo hemorrhagic fever in Zahedan, southeast of Iran: a comparative study. Arch Iranian Med 2009; 12: 151-153.
5. Sharifi Mood B, Mardani M, Metanat M. Clinical manifestations, laboratory findings and clinical outcome in pregnant women with Crimean-Congo hemorrhagic fever. Iranian J Clin Infect Dis 2007; 2: 193-196.
6. Sheikh AS, Sheikh AA, Sheikh NS et al. Ribavirin: an effective treatment of Crimean-Congo haemorrhagic fever. Pak J Med Sci 2004; 20: 201-206.
7. Sharifi-Mood B, Alavi-Naini R, Metanat M et al. Ribavirin: an effective drug for treatment of children with Crimean-Congo hemorrhagic fever. A seven-year experience. Pakistan J Bio Sci 2006; 9: 1898-1600.
8. Ergonul O, Celikbas A, Dokuzoguz B et al. Characteristics of patients with Crimean-Congo hemorrhagic fever in a recent outbreak in Turkey and impact of oral ribavirin therapy. Clin Infect Dis 2004; 39: 284-287.
9. Centers for Disease Control and Prevention. Viral hemorrhagic fever: Initial management of suspected and confirmed cases. MMWR Morb Mortal Wkly Rep 1983; 32(Suppl 2): 27-38.
10. Mardani M, Jahromi MK, Naieni KH et al. The efficacy of oral ribavirin in the treatment of Crimean-Congo hemorrhagic fever in Iran. Clin Infect Dis 2003; 36: 1613-1618.
11. Mirazimi A Old and new treatment strategies. In: Ergonul O, Whitehouse CA (eds). Crimean-Congo Hemorrhagic Fever: A Global Perspective, Dordrecht: Springer, 2007, pp. 258-260.
12. Kubar A, Haciomeroglu M, Ozkul A et al. Administration of Crimean-Congo hemorrhagic fever (CCHF) virus hyperimmunoglobulin in Patients diagnosed with CCHF and viral load monitorization by reverse transcriptase-PCR. Jpn J Infect Dis 2011; 64: 439-443.
13. Ozkurt Z, Kiki I, Erol S et al. Crimean-Congo hemorrhagic fever in Eastern Turkey: clinical features, risk factors and efficacy of ribavirin therapy. J Infect 2006; 52: 207-215.
14. Ergonul O Clinical and pathologic features of Crimean Congo hemorrhagic fever. In: Ergonul O, Whitehouse CA (eds). Crimean Congo Hemorrhagic Fever: A Global Perspective, Dordrecht: Springer, 2007, pp. 207-220.
15. Pantanowitz L. Mechanisms of thrombocytopenia in tick-borne diseases. Internet J Infect Dis 2003; 2. http://www.ispub.com/ostia/index.php (last accessed on 18 October 2004).
16. Dilber E, Cakir M, Erduran E et al. High-dose methylprednisolone in children with Crimean-Congo haemorrhagic fever. Trop Doct 2010; 40: 27-30.
17. Metanat M, Sharifi-Mood B, Salehi M et al. Clinical outcomes in Crimean-Congo hemorrhagic fever: a five-year experience in the treatment of patients with oral ribavirin. Int J Virol 2006; 2: 21-24.
18. Izadi S, Salehi M. Evaluation of the efficacy of ribavirin therapy on survival of Crimean-Congo hemorrhagic fever patients: a case-control study. Jpn J Infect Dis 2009; 62: 11-15.
19. Weber F, Mirazimi A. Interferon and cytokine responses to Crimean Congo hemorrhagic fever virus; an emerging and neglected viral zonoosis. Cytokine Growth Factor Rev 2008; 19: 395-404.
20. Saksida A, Duh D, Wraber B et al. Interacting roles of immune mechanisms and viral load in the pathogenesis of Crimean-Congo hemorrhagic fever. Clin Vaccine Immunol 2010; 17: 1086-1093.